Jeff Yass’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-68,900
Closed -$2.68M 10505
2017
Q3
$2.68M Buy
+68,900
New +$2.53M ﹤0.01% 3407
2017
Q2
Sell
-7,900
Closed -$210K 10480
2017
Q1
$210K Sell
7,900
-12,700
-62% -$315K ﹤0.01% 7926
2016
Q4
$457K Buy
20,600
+1,900
+10% +$35.5K ﹤0.01% 7189
2016
Q3
$346K Sell
18,700
-12,400
-40% -$215K ﹤0.01% 6703
2016
Q2
$505K Sell
31,100
-24,600
-44% -$414K ﹤0.01% 6111
2016
Q1
$786K Sell
55,700
-2,700
-5% -$36.5K ﹤0.01% 5567
2015
Q4
$996K Buy
58,400
+15,900
+37% +$310K ﹤0.01% 5398
2015
Q3
$878K Buy
+42,500
New +$872K ﹤0.01% 6043

Other funds holding NDRM

Jeff Yass's NDRM Position: Q2 2017 in Review

Jeff Yass sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q2 2017, closing a stake of 31,765 shares — an estimated $823K sold.

Jeff Yass first reported a position in NDRM in Q1 2017 and held it in 1 quarter. The position peaked at $843K in Q1 2017. 73 funds tracked by Wall St. Rank hold NDRM as of Q2 2017.

  • Jeff Yass reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Jeff Yass sold 31,765 NeuroDerm Ltd. Ordinary Shares shares in Q2 2017, an estimated $823K.
  • Jeff Yass first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 1 quarter.
  • Jeff Yass's NeuroDerm Ltd. Ordinary Shares position peaked at $843K in Q1 2017.
  • 73 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q2 2017.

Based on Susquehanna International Group's 13F filing for Q2 2017, filed 15 Aug 2017.